JAK
Os inibidores de JAK (Janus quinase) são compostos que têm como alvo a via de sinalização JAK-STAT, que está envolvida no crescimento celular, na resposta imunológica e na angiogênese. Ao inibir JAK, esses compostos podem reduzir a sinalização que leva à formação de novos vasos sanguíneos em tumores, inibindo assim o crescimento tumoral. Os inibidores de JAK são importantes no tratamento de cânceres e doenças inflamatórias. Na CymitQuimica, oferecemos uma ampla gama de inibidores de JAK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 254 produtos para "JAK".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
Tyrphostin AG 490
CAS:Fórmula:C17H14N2O3Pureza:>98.0%(HPLC)(T)Cor e Forma:White to Light yellow powder to crystalPeso molecular:294.31WHI-P180 Hydrochloride
CAS:Fórmula:C16H15N3O3·HClPureza:>97.0%(HPLC)(T)Cor e Forma:White to Light gray to Light yellow powder to crystalPeso molecular:333.77WHI-P154
CAS:Fórmula:C16H14BrN3O3Pureza:>98.0%(HPLC)Cor e Forma:White to Yellow to Orange powder to crystalPeso molecular:376.21Pumecitinib
CAS:Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.Fórmula:C17H20N8O2SPureza:99.93%Cor e Forma:SoildPeso molecular:400.458Nimucitinib
CAS:Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.Fórmula:C25H26F2N6O2Pureza:99.58%Cor e Forma:Yellow SolidPeso molecular:480.5097Brepocitinib P-Tosylate
CAS:Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).Fórmula:C25H29F2N7O4SPureza:99.82% - 99.97%Cor e Forma:SolidPeso molecular:561.604Gusacitinib
CAS:Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).Fórmula:C24H28N8O2Pureza:98.06% - 99.94%Cor e Forma:SolidPeso molecular:460.5315JAK2 Inhibitor V
CAS:JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.Fórmula:C23H24N2OPureza:98.36% - 99.15%Cor e Forma:SolidPeso molecular:344.4495Ilginatinib maleate
CAS:Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C25H24FN7O4Pureza:99.74% - 99.82%Cor e Forma:SolidPeso molecular:505.501Delgocitinib
CAS:Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.Fórmula:C16H18N6OPureza:99.95%Cor e Forma:White SolidPeso molecular:310.3537Ilginatinib hydrochloride
CAS:Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C21H21ClFN7Pureza:99.55%Cor e Forma:SolidPeso molecular:425.89N-(3-Aminopropyl)cyclohexylamine
CAS:N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.Fórmula:C9H20N2Pureza:98.82% - 99.98%Cor e Forma:SolidPeso molecular:156.2685Ilginatinib
CAS:Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.Fórmula:C21H20FN7Pureza:98.4% - 99.01%Cor e Forma:SolidPeso molecular:389.4288WDR5-IN-6
CAS:WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6Fórmula:C13H8Cl2N2O2SPureza:99.69%Cor e Forma:SoildPeso molecular:327.186Golidocitinib
CAS:Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).Fórmula:C25H31N9O2Pureza:98.87% - 99.88%Cor e Forma:Yellow SolidPeso molecular:489.5727JAK3-IN-15
JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.Cor e Forma:Odour SolidGusacitinib-d4
Gusacitinib-d4 (ASN-002-d4) is the deuterium-labeled form of Gusacitinib. Gusacitinib (ASN-002) is an orally effective dual kinase inhibitor targeting SYK and JAK. It exhibits IC50 values of 5, 46, 4, 11, and 8 nM for SYK, JAK1, JAK2, JAK3, and TYK2, respectively. This compound effectively and rapidly suppresses key inflammatory pathways involved in the pathogenesis of atopic dermatitis. Gusacitinib is also used in research for conditions such as chronic hand eczema and basal cell carcinoma.JAK1/TYK2-IN-1
CAS:JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).Fórmula:C18H20F3N7OCor e Forma:SolidPeso molecular:407.401WDR5 ligand 2
CAS:WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.Fórmula:C29H31F3N4O4Cor e Forma:SolidPeso molecular:556.576JAK-IN-15
CAS:JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).Fórmula:C22H23FN4O3SCor e Forma:SolidPeso molecular:442.51
